Fig. 5
From: CD133 significance in glioblastoma development: in silico and in vitro study
The cell cycle assay for studying the cell cycle phase distribution of U87MG cells. A The cell cycle phase distribution of the control group, B the cell cycle phase distribution of the CD133-silenced group, C the cell cycle phase distribution of the temozolomide-treated group, D the cell cycle phase distribution of the combined treatment group, E the cell cycle phase distribution of studied groups. CD133 silencing leads to the accumulation of cells at the sub-G1 phase. F the mRNA expression of CDK4 in different studied groups. CD133 silencing downregulates the expression of CDK4 in U87MG cells. **P-value ≤ 0.01, and ****P-value ≤ 0.0001